Abstract

Shiga toxin (Stx) is the principal virulence factor during Shiga toxin-producing Escherichia coli (STEC) infections. We have previously reported the inactivation of bacteriophage encoding Stx after treatment with chitosan, a linear polysaccharide polymer with cationic properties. Cationic antimicrobial peptides (cAMPs) are short linear aminoacidic sequences, with a positive net charge, which display bactericidal or bacteriostatic activity against a wide range of bacterial species. They are promising novel antibiotics since they have shown bactericidal effects against multiresistant bacteria. To evaluate whether cationic properties are responsible for bacteriophage inactivation, we tested seven cationic peptides with proven antimicrobial activity as anti-bacteriophage agents, and one random sequence cationic peptide with no antimicrobial activity as a control. We observed bacteriophage inactivation after incubation with five cAMPs, but no inactivating activity was observed with the random sequence cationic peptide or with the non-alpha helical cAMP Omiganan. Finally, to confirm peptide-bacteriophage interaction, zeta potential was analyzed by following changes on bacteriophage surface charges after peptide incubation. According to our results we could propose that: (1) direct interaction of peptides with phage is a necessary step for bacteriophage inactivation, (2) cationic properties are necessary but not sufficient for bacteriophage inactivation, and (3) inactivation by cationic peptides could be sequence (or structure) specific. Overall our data suggest that these peptides could be considered a new family of molecules potentially useful to decrease bacteriophage replication and Stx expression.

Highlights

  • Infections with Shiga toxin-producing Escherichia coli (STEC) strains are a serious public health problem

  • Because the gene encoding for Shiga toxin (Stx) is inside the prophage genome, these strains are known as Escherichia coli Shiga

  • In addition we performed a minimal inhibitory activity (MIC) assay for these peptides at different concentrations between 54 and 3.3 μg/ml on the E. coli C600 TOX:green fluorescent protein (GFP) strain, and we found no antimicrobial activity below 27 μg/ml for all the peptides tested

Read more

Summary

Introduction

Infections with Shiga toxin-producing Escherichia coli (STEC) strains are a serious public health problem. Children infected with STEC strains present diarrhea, hemorrhagic colitis, and a percentage of patients can develop Hemolytic Uremic Syndrome (HUS). Shiga toxin (Stx) is the main virulence factor during STEC infections. Because the gene encoding for Stx is inside the prophage genome, these strains are known as Escherichia coli Shiga. During STEC infection, the bacteriophage is cleaved and the replication and Stx expression take place inside the gut. Free bacteriophages are able to infect other susceptible bacteria present in the gut, exacerbating Stx expression (Cornick et al, 2006). There are no effective treatments or vaccines available, and for this reason bacteriophage inactivation treatments are a promising strategy to prevent Stx expression after STEC infections

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call